TerminatedPhase 2NCT01465386

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fred Hutchinson Cancer Center
Principal Investigator: John Pagel, MD PhD
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Intervention: bortezomib(drug)
Enrollment: 6 enrolled
Eligibility: 18 years · All sexes
Timeline: 2011 – 2015

Study locations (1)

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01465386 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials